Dr. John W. Day, MD
Physical Medicine & Rehabilitation (PM&R) (Neuromuscular Medicine (Psychiatry & Neurology) Physician)
300 Pasteur Dr
Stanford, CA 94305
Who else practices at this address →
Santa Clara County includes mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Minnesota Medical School (1977)
- Years since graduation
- 49
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 37
Licensed in California since 2011, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1977Medical school: University of Minnesota Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neuromuscular Medicine (Psychiatry & Neurology) Physician primary
CA license G52734 (first issued 2011; current) -
Neurology Physician
CA license G52734 (first issued 2011; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Physical Medicine & Rehabilitation (PM&R) per capita by county →
Where they work
Hospitals
- Stanford Health Care Stanford, CA
Medical groups
- Stanford Health Care (3,122 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 37
- Services billed
- 53
- Patients’ average age
- 63
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 28 | 26 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 20 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Skyclarys (omaveloxolone) | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 11 payments worth $21,660 in total to this clinician.
| F. Hoffmann-la Roche AG | $5,848 |
|---|---|
| Genzyme Corporation | $3,975 |
| Sarepta Therapeutics, Inc. | $3,475 |
| Novartis Pharma AG | $3,362 |
| Sanofi US Services Inc. | $2,725 |
| Novartis Pharmaceuticals Corporation | $1,650 |
| Argenx US, Inc. | $625 |
| Consulting Fee | $20,309 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $1,250 |
| Food and Beverage | $100 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sarepta Therapeutics, Inc. Apr 24, 2025 | Consulting Fee Elevidys · Genetic Disease | $3,375 |
| Novartis Pharma AG Jul 25, 2025 | Consulting Fee ZOLGENSMA · Neurology | $3,362 |
| F. Hoffmann-la Roche AG Nov 19, 2025 | Consulting Fee | $2,800 |
| Genzyme Corporation Jan 27, 2025 | Consulting Fee | $2,725 |
| Sanofi US Services Inc. Jan 27, 2025 | Consulting Fee | $2,725 |
| F. Hoffmann-la Roche AG Jun 27, 2025 | Consulting Fee | $1,960 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Consulting Fee ZOLGENSMA · Neurology | $1,650 |
| Genzyme Corporation Aug 16, 2025 | Compensation for services other than consulting (speaking, faculty) NEXVIAZYME · Genetic Disease · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $1,250 |
| F. Hoffmann-la Roche AG Apr 1, 2025 | Consulting Fee | $1,088 |
| Argenx US, Inc. Jul 23, 2025 | Consulting Fee | $625 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 14 industry-funded studies in 2025, from 7 companies. The companies reported $501,459 in research payments for these studies, mostly to the institutions running them.
- A Long-Term Extension Study of Nusinersen (BIIB058) Administered at Higher Doses in Participants With Spinal Muscular Atrophy Who Previously Participated in an Investigational Study with Nusinersen.
Biogen, Inc. - Nusinersen in Adults with Spinal Muscular Atrophy: An Open Label Study to Assess Efficacy and Exploratory Endpoints
Biogen, Inc. - A Phase 3b Study to Evaluate Higher Dose Nusinersen (BIIB058) in Patients with Spinal Muscular Atrophy Previously Treated with Risdiplam
Biogen, Inc. - A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101
Novartis Pharmaceuticals Corporation - RO7034067 in adult and pediatric patients with spinal muscular atrophy
Hoffmann-la Roche Limited - ION363CS1
Ionis Pharmaceuticals, Inc. - A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients With Alexander Disease
Ionis Pharmaceuticals, Inc. - A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort
Sarepta Therapeutics, Inc. · Recruiting · NCT04626674 - An Open Label, Single Cohort Study to Assess the Pharmacokinetic Profile of Nusinersen (BIIB058) Administered Via the ThecaFlex DRx System (PIERRE-PK)
Biogen, Inc. - Risdiplam post gene therapy study plateau symptoms study 2
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.